Overview
- 12 inspections across 11 sites are on record.
- 1 Form 483 observation is attributed to this investigator.
- Most recent recorded activity is 2024-03-29.
At a glance
Inspections
12
Sites
11
Observations
1
Career since
Jul 2018
Recent inspections
Most recent inspections in the published record.
| Site | Date | Category | Form 483 |
|---|---|---|---|
| Chugai Pharma Manufacturing Co., Ltd | 29 Mar 2024 | Human Drugs | On file |
| AbbVie Bioresearch Center | 30 Jan 2024 | Human Drugs | On file |
| Samsung Biologics Co., Ltd. | 1 Sep 2023 | Human Drugs | On file |
| Alexion Pharma International Operations Limited | 24 Jan 2023 | Human Drugs | On file |
| SEAGEN INC. | 10 Jun 2022 | Human Drugs | On file |
Sites inspected
Chugai Pharma Manufacturing Co., LtdKita, Japan1 insp.
AbbVie Bioresearch CenterWorcester, United States1 insp.
Samsung Biologics Co., Ltd.Yeonsu District, Korea (the Republic of)1 insp.
Alexion Pharma International Operations LimitedDublin 15, Ireland1 insp.
SEAGEN INC.Bothell, United States1 insp.
Co-investigators
Investigators who share inspections with this person.
Zhong Li3 shared
Michael Shanks3 shared
Hamet M Toure2 shared
Hyung-Yul Lee1 shared
Dogbeda F Mackenzie1 shared
Wayne E Seifert1 shared
Jeffrey P Raimondi1 shared
Wendy G Tan1 shared
Christopher R Czajka1 shared
Matthew B Casale1 shared
Full investigator report
Get the verbatim findings behind Jacek Cieslak's 1 observation
Source 483 PDFs, verbatim observations, and how each site responded, so your team knows what they cite before they arrive.
- New inspections and Form 483s, mapped to the CFR citation
- Warning letter outcomes, and the citation patterns they repeat
- Their co-investigators, so no surprises about who shows up on site